Berberine alleviates dextran sodium sulfate-induced colitis by improving intestinal barrier function and reducing inflammation and oxidative stress

Experimental and Therapeutic Medicine

Volumn 13, Issue 6, 2017, Pages 3374-3382

  Zhang, Li Chao ^a   Wang, Yue ^b   Tong, Ling Chang ^c   Sun, Sheng ^c   Liu, Wei Ye ^c   Zhang, Su ^a,c   Wang, Rong Mei ^c   Wang, Zhi Bin ^c   Li, Ling ^c  

^a Shanghai Municipal Hospital of Traditional Chinese Medicine   (China)

^b NINGXIA MEDICAL UNIVERSITY   (China)

^c SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Berberine; Dextran sulfate sodium; Inflammation; Intestinal barrier function; Tight junction protein; Ulcerative colitis

Indexed keywords

BERBERINE; CADHERIN; CATALASE; CD68 ANTIGEN; INTERLEUKIN 1BETA; INTERLEUKIN 6; MYELOPEROXIDASE; OCCLUDIN; PROTEIN ZO1; STAT3 PROTEIN; SUPEROXIDE DISMUTASE; TUMOR NECROSIS FACTOR;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON INJURY; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DRUG EFFICACY; ENZYME ACTIVITY; FECES ANALYSIS; HISTOPATHOLOGY; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; INFLAMMATION; INTESTINE FUNCTION; INTESTINE MUCOSA PERMEABILITY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; OXIDATIVE STRESS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WEIGHT REDUCTION; WESTERN BLOTTING;

EID: 85019087864     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2017.4402     Document Type: Article

References (46)

1. Deuring JJ, de Haar C, kuipers EJ, Peppelenbosch MP and van der Woude CJ: The cell biology of the intestinal epithelium and its relation to inflammatory bowel disease. Int J Biochem Cell Biol 45: 798-806, 2013.
2. Burisch J and Munkholm P: The epidemiology of inflammatory bowel disease. Scand J Gastroenterol 50: 942-951, 2015.
3. Burisch J, Jess T, Martinato M and Lakatos PL; ECCO-EpiCom: The burden of inflammatory bowel disease in Europe. J Crohns Colitis 7: 322-337, 2013.
4. Sobrado CW, Leal RF and Sobrado LF: Therapies for Crohn's disease: A clinical update. Arq Gastroenterol 53: 206-211, 2016.
5. Iskandar HN, Dhere T and Farraye FA: Ulcerative Colitis: Update on medical management. Curr Gastroenterol Rep 17: 44, 2015.
6. Kong W, Wei J, Abidi P, Lin M, Inaba S, Li C, Wang Y, Wang Z, Si S, Pan H, et al: Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351, 2004.
7. Jin Y, Khadka DB and Cho WJ: Pharmacological effects of berberine and its derivatives: A patent update. Expert Opin Ther Pat 26: 229-243, 2016.
8. Kumar A, Ekavali Chopra K, Mukherjee M, Pottabathini R and Dhull DK: Current knowledge and pharmacological profile of berberine: An update. Eur J Pharmacol 761: 288-297, 2015.
9. Lee IA, Hyun YJ and Kim DH: Berberine ameliorates TNBS-induced colitis by inhibiting lipid peroxidation, enterobac-terial growth and NF-κB activation. Eur J Pharmacol 648: 162-170, 2010.
10. Zhou H and Mineshita S: The effect of berberine chloride on experimental colitis in rats in vivo and in vitro. J Pharmacol Exp Ther 294: 822-829, 2000.
11. Yan F, Wang L, Shi Y, Cao H, Liu L, Washington MK, Chaturvedi R, Israel DA, Cao H, Wang B, et al: Berberine promotes recovery of colitis and inhibits inflammatory responses in colonic macrophages and epithelial cells in DSS-treated mice. Am J Physiol Gastrointest Liver Physiol 302: G504-G514, 2012.
12. Cui HS, Hayasaka S, Zhang XY, Hayasaka Y, Chi ZL and Zheng LS: Effect of berberine on barrier function in a human retinal pigment epithelial cell line. Jpn J Ophthalmol 51: 64-67, 2007.
13. Zhang DM, Liu HY, Xie L and Liu XD: Effect of baicalin and berberine on transport of nimodipine on primary-cultured, rat brain microvascular endothelial cells. Acta Pharmacol Sin 28: 573-578, 2007.
14. Li N, Gu L, Qu L, Gong J, Li Q, Zhu W and Li J: Berberine attenuates pro-inflammatory cytokine-induced tight junction disruption in an in vitro model of intestinal epithelial cells. Eur J Pharm Sci 40: 1-8, 2010.
15. Cao M, Wang P, Sun C, He W and Wang F: Amelioration of IFN-γ and TNF-α-induced intestinal epithelial barrier dysfunction by berberine via suppression of MLCK-MLC phosphorylation signaling pathway. PLoS One 8: e61944, 2013.
16. Wirtz S, Neufert C, Weigmann B and Neurath MF: Chemically induced mouse models of intestinal inflammation. Nat Protoc 2: 541-546, 2007.
17. Nauseef WM: Myeloperoxidase in human neutrophil host defence. Cell Microbiol 16: 1146-1155, 2014.
18. Moussaoui N, Braniste V, Ait-Belgnaoui A, Gabanou M, Sekkal S, Olier M, Théodorou V, Martin PG and Houdeau E: Changes in intestinal glucocorticoid sensitivity in early life shape the risk of epithelial barrier defect in maternal-deprived rats. PLoS One 9: e88382, 2014.
19. Zhang LC, Li ZZ, Yu YS, Wang ZB, Wei X, Su DF and Li L: Angiotensin-converting enzyme and angiotensin-converting enzyme 2 are involved in sinoaortic denervation-induced cardiovascular hypertrophy in rats. Biol Pharm Bull 34: 1398-1403, 2011.
20. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C (T)) Method. Methods 25: 402-408, 2001.
21. Liu WY, Wang ZB, Wang Y, Tong LC, Li Y, Wei X, Luan P and Li L: Increasing the permeability of the blood-brain barrier in three different models in vivo. CNS Neurosci Ther 21: 568-574, 2015.
22. Liang GH and Weber CR: Molecular aspects of tight junction barrier function. Curr Opin Pharmacol 19: 84-89, 2014.
23. Nguyen PM, Putoczki TL and Ernst M: STAT3-activating cytokines: A therapeutic opportunity for inflammatory bowel disease? J Interferon Cytokine Res 35: 340-350, 2015.
24. Xu AT, Li Y, Zhao D, Shen J, Xu XT, Qiao YQ, Zhu MM, Wang TR, Cui Y, Ai LY and Ran ZH: High suppressor of cytokine signaling-3 expression impairs STAT3-dependent protective effects of interleukin-22 in ulcerative colitis in remission. Inflamm Bowel Dis 21: 241-250, 2015.
25. Piechota-Polanczyk A and Fichna J: Review article: The role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol 387: 605-620, 2014.
26. Salvo Romero E, Alonso Cotoner C, Pardo Camacho C, Casado Bedmar M and Vicario M: The intestinal barrier function and its involvement in digestive disease. Rev Esp Enferm Dig 107: 686-696, 2015.
27. Sánchez de Medina F, Romero-Calvo I, Mascaraque C and Martinez-Augustin O: Intestinal inflammation and mucosal barrier function. Inflamm Bowel Dis 20: 2394-2404, 2014.
28. Lee SH: Intestinal permeability regulation by tight junction: Implication on inflammatory bowel diseases. Intest Res 13: 11-18, 2015.
29. Liu WY, Wang ZB, Zhang LC, Wei X and Li L: Tight junction in blood-brain barrier: An overview of structure, regulation and regulator substances. CNS Neurosci Ther 18: 609-615, 2012.
30. Kucharzik T, Walsh SV, Chen J, Parkos CA and Nusrat A: Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol 159: 2001-2009, 2001.
31. Chen Y, Zhang HS, Fong GH, Xi QL, Wu GH, Bai CG, Ling ZQ, Fan L, Xu YM, Qin YQ, et al: PHD3 stabilizes the tight junction protein occludin and protects intestinal epithelial barrier function. J Biol Chem 290: 20580-20589, 2015.
32. Vivinus-Nébot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, et al: Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation. Gut 63: 744-752, 2014.
33. Fries W, Belvedere A and Vetrano S: Sealing the broken barrier in IBD: Intestinal permeability, epithelial cells and junctions. Curr Drug Targets 14: 1460-1470, 2013.
34. Merga Y, Campbell BJ and Rhodes JM: Mucosal barrier, bacteria and inflammatory bowel disease: Possibilities for therapy. Dig Dis 32: 475-483, 2014.
35. Chen G, Yang Y, Liu M, Teng Z, Ye J, Xu Y, Cai X, Cheng X, Yang J, Hu C, et al: Banxia xiexin decoction protects against dextran sulfate sodium-induced chronic ulcerative colitis in mice. J Ethnopharmacol 166: 149-156, 2015.
36. Li C, Xi Y, Li S, Zhao Q, Cheng W, Wang Z, Zhong J, Niu X and Chen G: Berberine ameliorates TNBS induced colitis by inhibiting inflammatory responses and Th1/Th17 differentiation. Mol Immunol 67: 444-454, 2015.
37. Wu SJ, Don TM, Lin CW and Mi FL: Delivery of berberine using chitosan/fucoidan-taurine conjugate nanoparticles for treatment of defective intestinal epithelial tight junction barrier. Mar Drugs 12: 5677-5697, 2014.
38. Kawano M, Takagi R, Kaneko A and Matsushita S: Berberine is a dopamine D1- and D2-like receptor antagonist and ameliorates experimentally induced colitis by suppressing innate and adaptive immune responses. J Neuroimmunol 289: 43-55, 2015.
39. Minaiyan M, Ghannadi A, Mahzouni P and Jaffari-Shirazi E: Comparative study of berberis vulgaris fruit extract and berberine chloride effects on acetic acid-induced colitis in rats. Iran J Pharm Res 10: 97-104, 2011.
40. Aggarwal BB, Kunnumakkara AB, Harikumar KB, Gupta SR, Tharakan ST, Koca C, Dey S and Sung B: Signal transducer and activator of transcription-3, inflammation, and cancer: How intimate is the relationship? Ann N Y Acad Sci 1171: 59-76, 2009.
41. Bourgeais J, Gouilleux-Gruart V and Gouilleux F: Oxidative metabolism in cancer: A STAT affair? JAKSTAT 2: e25764, 2013.
42. Egger B, Bajaj-Elliott M, MacDonald TT, Inglin R, Eysselein VE and Büchler MW: Characterisation of acute murine dextran sodium sulphate colitis: Cytokine profile and dose dependency. Digestion 62: 240-248, 2000.
43. Kitajima S, Takuma S and Morimoto M: Changes in colonic mucosal permeability in mouse colitis induced with dextran sulfate sodium. Exp Anim 48: 137-143, 1999.
44. - dendritic cell populations in the colonic mucosa of patients with Crohn's disease. Eur J Immunol 33: 143-151, 2003.
45. Vuckovic S, Florin TH, Khalil D, Zhang MF, Patel K, Hamilton I and Hart DN: CD40 and CD86 upregulation with divergent CMRF44 expression on blood dendritic cells in inflammatory bowel diseases. Am J Gastroenterol 96: 2946-2956, 2001.
46. Ghia JE, Galeazzi F, Ford DC, Hogaboam CM, Vallance BA and Collins S: Role of M-CSF-dependent macrophages in colitis is driven by the nature of the inflammatory stimulus. Am J Physiol Gastrointest Liver Physiol 294: G770-G777, 2008.